Yahoo Web Search

Search results

1. • 

     Is Geron Stock a Buy Following Its First New Drug Approval?

     Motley Fool via Yahoo Finance· 12 hours ago

     Around 30% of MDS cases progress to acute myeloid leukemia. Even for patients who don't progress to...

2. • Valrubicin-loaded immunoliposomes: A new technology to fight hematological cancer

     Medical Xpress· 2 days ago

     Valrubicin, a lipophilic chemical molecule similar to daunorubicin, has primarily been used in the treatment of bladder cancer. An article recently published in Cell Death ...

3. • 

     Cancer-fighting antibodies inject chemo directly into tumor cells, upping effectiveness

     NBC NEWS· 6 days ago

     The approach isn’t entirely new: The first antibody drug conjugate was approved by the Food and Drug...

4. • MD Anderson Research Highlights for June 5, 2024 | Newswise

     Newswise· 4 days ago

     The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These

5. • 'Smart warheads' of cancer: Experts' excitement for treatment approach grows

     Becker’s Hospital Review· 6 days ago

     Cancer experts are increasingly optimistic about the potential for antibody-drug conjugates to become a standard treatment approach. The therapies involve attaching chemotherapy to an antibody ...

6. • 

     Steps To-Marrow: Grandmother walks hundreds of miles to raise donor awareness

     The Wenatchee World· 3 days ago

     Jeana Moore, 71, is not singing “I’m Gonna Be,” but she is walking hundreds of miles, thousands one...

7. • HUTCHMED Initiates Phase I Trial of Menin Inhibitor HMPL-506 in Patients with Hematological...

     Benzinga· 2 days ago

     HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 06, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated Phase I clinical trial of its menin

8. • 

     How a protein component of nuclear pore complexes | Newswise

     Newswise· 4 days ago

     Nuclear pore complexes (NPCs) are channels composed of multiple proteins that ferry molecules in and...

9. • 

     AbbVie's (ABBV) Ovarian Cancer Therapy Meets Study Goal

     Zacks via Yahoo Finance· 1 day ago

     Data from a mid-stage study shows that treatment with AbbVie's (ABBV) Elahere achieves an objective...

10. • FDA Approves Imetelstat for Rare Low-Risk Blood Cancer

      Medscape· 2 days ago

      The approval for the first-in-class agent is "potentially practice changing" given the lack of treatment options for transfusion-dependent lower-risk MDS patients.